Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: an Open-label, Single-arm, Single-center Phase Ib/II Clinical Study

NCT07334431 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.

NCT NCT07334431
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07334431 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: an Open-label, Single-arm, Single-center Phase Ib/II Clinical Study
Lead sponsor
Henan Cancer Hospital
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 22, 2024
Completion date
December 31, 2026
Enrollment
45 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

first-line therapy, fruquintinib, gastric (stomach) cancer, gastric adenocarcinoma, gej adenocarcinoma, her2-positive gastric cancer